Related Experiment Videos
The CFTR-mediated protein secretion defect: pharmacological correction.
M A McPherson1, M M Pereira, D Russell
1Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK.
Pflugers Archiv : European Journal of Physiology
|February 15, 2002
Summary
Researchers explored pharmacological methods to fix defective protein secretion in cystic fibrosis (CF) airway cells. Certain compounds corrected CFTR function, offering potential for new CF therapies.
Area of Science:
- Cell Biology
- Pharmacology
- Genetics
Background:
- Cystic fibrosis (CF) is characterized by defective protein secretion in airway glands, leading to viscous mucus.
- The cystic fibrosis transmembrane conductance regulator (CFTR) is crucial for secreting mucins and serous proteins.
Purpose of the Study:
- To pharmacologically correct CFTR defects in airway gland cells to address viscous mucus in CF.
- To investigate strategies including direct CFTR activation, bypass of CFTR pathways, and DeltaF508-CFTR trafficking.
Main Methods:
- Tested compounds related to IBMX, including phosphodiesterase inhibitors and adenosine receptor antagonists (CPT, CPX).
- Utilized CFTR antibody-inhibited submandibular gland cells and DeltaF508/DeltaF508-CFTR nasal gland cells.
- Investigated glycoprotein secretion in Calu-3 cells and DeltaF508-CFTR trafficking using confocal imaging.
Main Results:
- Compounds CPT and CPX corrected defective beta-adrenergic stimulation of mucin secretion in submandibular cells.
- CPT also corrected lactoferrin secretion in nasal gland cells with DeltaF508-CFTR mutation.
- Pharmacological correction occurred without excessive cyclic AMP increase and did not require enhanced CFTR Cl(-) channel activity.
- Confocal imaging revealed partialDeltaF508-CFTR colocalization with CD59 at the apical membrane, but significant mislocalization within the cell.
Conclusions:
- Pharmacological correction of CFTR-mediated protein secretion is achievable.
- These findings suggest a promising avenue for developing rational drug therapies for cystic fibrosis patients.
- The mechanism involves direct CFTR interaction, not solely cyclic AMP elevation or increased channel activity.